AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer

被引：0
|
作者：
Smyth, Lillian M.
Oliveira, Mafalda
Ciruelos, Eva
Tamura, Kenji
El-Khoueiry, Anthony
Mita, Alain
You, Benoit
Renouf, Daniel J.
Sablin, Marie-Paule
Lluch, Ana
Mayer, Ingrid A.
Bando, Hideaki
Yamashita, Hiroko
Ambrose, Helen
de Bruin, Elza
Carr, T. Hedley
Corcoran, Claire
Foxley, Andrew
Lindemann, Justin P. O.
Maudsley, Rhiannon
Pass, Martin
Rutkowski, Andrzej
Schiavon, Gaia
Banerji, Udai
Scaltriti, Maurizio
Taylor, Barry S.
Chandarlapaty, Sarat
Baselga, Jose
Hyman, David M.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[3] Hosp Univ 12 Octubre, Madrid, Spain
[4] Natl Canc Ctr, Tokyo, Japan
[5] Univ Southern Calif, Los Angeles, CA USA
[6] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[7] Univ Lyon 1, Inst Cancerol, Hosp Civils Lyon, CITOHL, Lyon, France
[8] British Columbia Canc Agcy, Vancouver, BC, Canada
[9] Inst Curie, Paris, France
[10] Inst Curie, St Cloud, France
[11] Hosp Clin Univ, Valencia, Spain
[12] INCLIVA Hlth Res Inst, Valencia, Spain
[13] Univ Valencia, Valencia, Spain
[14] CIBERONC ISCIII, Valencia, Spain
[15] Vanderbilt Breast Ctr, Nashville, TN USA
[16] Hosp East, Natl Canc Ctr, Chiba, Japan
[17] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan
[18] AstraZeneca, Cambridge, England
[19] Inst Canc Res, London, England
[20] Royal Marsden NHS Fdn Trust, London, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-21-32
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PIK3CA mutations contribute to fulvestrant resistance in ER-positive breast cancer
    Huang, Doudou
    Tang, Lin
    Yang, Fang
    Jin, Juan
    Guan, Xiaoxiang
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2019, 11 (09): : 6055 - 6065
  • [32] Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT) (vol 26, pg 1574, 2020)
    Robertson, John F. R.
    Coleman, Robert E.
    Cheung, Kwok-Leung
    Evans, Abigail
    Holcombe, Chris
    Skene, Anthony
    Rea, Daniel
    Ahmed, Samreen
    Jahan, Ali
    Horgan, Kieran
    Rauchhaus, Petra
    Littleford, Roberta
    Cheung, S. Y. Amy
    Cullberg, Marie
    de Bruin, Elza C.
    Koulai, Loumpiana
    Lindemann, Justin P. O.
    Pass, Martin
    Rugman, Paul
    Schiavon, Gaia
    Deb, Rahul
    Finlay, Pauline
    Foxley, Andrew
    Gee, Julia M. W.
    CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5469 - 5469
  • [33] Is fulvestrant more effective than tamoxifen for treating ER-positive breast cancer in postmenopausal women?
    Vinod Raina
    Nature Clinical Practice Oncology, 2004, 1 : 20 - 21
  • [34] The AKT inhibitor AZD5363 is selectively active in PIK3CA mutant gastric cancer cell lines, and sensitizes a gastric cancer explant model to docetaxel
    Li, Jing
    Davies, Barry R.
    Zhou, Minhua
    Zhang, Jingchuan
    Xu, Yan
    Tang, Lili
    Wang, Huiying
    Liu, Charles
    Yin, Xiaolu
    Ji, Qunsheng
    Yu, Derek Dehua
    CANCER RESEARCH, 2012, 72
  • [35] AKT inhibitor AZD5363 suppresses stemness and promotes anti-cancer activity of 3,3′-diindolylmethane in human breast cancer cells
    Zhu, Kaiyuan
    Liu, Xu
    Liu, Chunxiao
    Xu, Yuting
    Fu, Yingqiang
    Dong, Wei
    Yan, Yadong
    Wang, Wenjing
    Qian, Cheng
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2021, 429
  • [36] The short term effects of an AKT inhibitor (AZD5363) on biomarkers of the AKT pathway and anti-tumour activity in a breast cancer paired biopsy study (STAKT trial)
    Roberston, J. F. R.
    Cheung, K. L.
    Ahmed, S.
    Coleman, R. E.
    Evans, A.
    Holcombe, C.
    Rea, D.
    Rauchhaus, P.
    Skene, A.
    Littleford, R.
    Jahan, A.
    Kelly, S.
    Lindermann, J. P. O.
    Horgan, K.
    Foxley, A.
    Rugman, P.
    Pass, M.
    CANCER RESEARCH, 2017, 77
  • [37] Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-a Axis
    Xu, Tong
    Jiang, Yanyu
    Yuan, Shuying
    Zhang, Li
    Chen, Xihui
    Zhao, Weili
    Cai, Lili
    Xiao, Biying
    Jia, Lijun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [38] Lasofoxifene alone or in combination with palbociclib as an effective treatment for therapy-resistant ER-positive metastatic breast cancer
    Laine, Muriel
    Kurleto, Justyna D.
    Greene, Marianne E.
    Phung, Linda
    Komm, Barry S.
    Greene, Geoffrey L.
    CANCER RESEARCH, 2020, 80 (16)
  • [39] The AKT inhibitor AZD5363 elicits synthetic lethality in ARID1A-deficient gastric cancer cells via induction of pyroptosis
    Fang, Menghan
    Lin, Youfen
    Xue, Chaorong
    Sheng, Kaiqin
    Guo, Zegeng
    Han, Yuting
    Lin, Hanbin
    Wu, Yuecheng
    Sang, Yuchao
    Chen, Xintan
    Howell, Stephen B.
    Lin, Xu
    Lin, Xinjian
    BRITISH JOURNAL OF CANCER, 2024, 131 (06) : 1080 - 1091
  • [40] Targeting new therapies in combination with hormonal therapies for ER-positive breast cancer
    M Dowsett
    Breast Cancer Research, 7
12345